Advertisement

International Journal of Hematology

, Volume 87, Issue 5, pp 532–537 | Cite as

ESHAP therapy effective in a patient with Langerhans cell sarcoma

  • Akihide Yoshimi
  • Keiki Kumano
  • Toru Motokura
  • Yutaka Takazawa
  • Satoshi Oota
  • Shigeru Chiba
  • Tsuyoshi Takahashi
  • Masashi Fukayama
  • Mineo KurokawaEmail author
Case Report

Abstract

We describe the rare case of a 53-year-old woman with systemic involvement of Langerhans cell sarcoma (LCS) who had undergone living-related liver transplantation. We chose the CHOP regimen as first-line chemotherapy, and clinical improvement of LCS was obtained. Intensive care was necessary due to the systemic involvement of LCS and severe infectious diseases. After the third cycle of CHOP therapy, however, disease progression was observed, and we administrated a modified ESHAP regimen (etoposide, carboplatin, cytarabine, methylprednisolone) as second-line therapy. A marked response was obtained after four cycles of this combination chemotherapy. Modified ESHAP may be a very effective combination chemotherapy regimen for LCS.

Keywords

Langerhans cell sarcoma ESHAP Transplantation Histiocytosis Positron emission tomography Chemotherapy 

References

  1. 1.
    Ben-Ezra J, Bailey A, Azumi N, et al. Malignant histiocytosis X. A distinct clinicopathologic entity. Cancer. 1991;68:1050–60.CrossRefPubMedGoogle Scholar
  2. 2.
    Bohn OL, Ruiz-Arguelles G, Navarro L, Saldivar J, Sanchez-Sosa S. Cutaneous Langerhans cell sarcoma: a case report and review of the literature. Int J Hematol. 2007;85:116–20.CrossRefPubMedGoogle Scholar
  3. 3.
    Diaz-Sarrio C, Salvatella-Danes N, Castro-Forns M, Nadal A. Langerhans cell sarcoma in a patient who underwent transplantation. J Eur Acad Dermatol Venereol. 2007;21:973–6.CrossRefPubMedGoogle Scholar
  4. 4.
    Ferringer T, Banks PM, Metcalf JS. Langerhans cell sarcoma. Am J Dermatopathol. 2006;28:36–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Itoh H, Miyaguni H, Kataoka H, et al. Primary cutaneous Langerhans cell histiocytosis showing malignant phenotype in an elderly woman: report of a fatal case. J Cutan Pathol. 2001;28:371–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Julg BD, Weidner S, Mayr D. Pulmonary manifestation of a Langerhans cell sarcoma: case report and review of the literature. Virchows Arch. 2006;448:369–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Kawase T, Hamazaki M, Ogura M, et al. CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases. Int J Hematol. 2005;81:323–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Lee JS, Ko GH, Kim HC, Jang IS, Jeon KN, Lee JH. Langerhans cell sarcoma arising from Langerhans cell histiocytosis: a case report. J Korean Med Sci. 2006;21:577–80.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Misery L, Godard W, Hamzeh H, et al. Malignant Langerhans cell tumor: a case with a favorable outcome associated with the absence of blood dendritic cell proliferation. J Am Acad Dermatol. 2003;49:527–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Pileri SA, Grogan TM, Harris NL, et al. Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology. 2002;41:1–29.CrossRefPubMedGoogle Scholar
  11. 11.
    Tani M, Ishii N, Kumagai M, Ban M, Sasase A, Mishima Y. Malignant Langerhans cell tumour. Br J Dermatol. 1992;126:398–403.CrossRefPubMedGoogle Scholar
  12. 12.
    Wood C, Wood GS, Deneau DG, Oseroff A, Beckstead JH, Malin J. Malignant histiocytosis X. Report of a rapidly fatal case in an elderly man. Cancer. 1984;54:347–52.CrossRefPubMedGoogle Scholar
  13. 13.
    McKelvey EM, Gottlieb JA, Wilson HE, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–93.CrossRefPubMedGoogle Scholar
  14. 14.
    Velasquez W, McLaughlin P, Tucker S, et al. ESHAP––an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol. 1994;12:1169–76.CrossRefPubMedGoogle Scholar
  15. 15.
    Honda R, Ohno Y, Iwasaki T, et al. Langerhans’ cell histiocytosis after living donor liver transplantation: report of a case. Liver Transpl. 2005;11:1435–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Chu T. Langerhans cell histiocytosis. Australas J Dermatol. 2001;42:237–42.CrossRefPubMedGoogle Scholar
  17. 17.
    Stockschlaeder M, Sucker C. Adult Langerhans cell histiocytosis. Eur J Haematol. 2006;76:363–8.CrossRefPubMedGoogle Scholar
  18. 18.
    Akkari V, Donadieu J, Piguet C, et al. Hematopoietic stem cell transplantation in patients with severe Langerhans cell histiocytosis and hematological dysfunction: experience of the French Langerhans Cell Study Group. Bone Marrow Transplant. 2003;31:1097–103.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2008

Authors and Affiliations

  • Akihide Yoshimi
    • 1
  • Keiki Kumano
    • 1
    • 2
  • Toru Motokura
    • 1
  • Yutaka Takazawa
    • 3
  • Satoshi Oota
    • 3
  • Shigeru Chiba
    • 1
    • 2
  • Tsuyoshi Takahashi
    • 1
  • Masashi Fukayama
    • 3
  • Mineo Kurokawa
    • 1
    Email author
  1. 1.Department of Hematology and Oncology, Graduate School of MedicineUniversity of TokyoTokyoJapan
  2. 2.Department of Cell Therapy and Transplantation MedicineUniversity of Tokyo HospitalTokyoJapan
  3. 3.Department of Pathology, Graduate School of MedicineUniversity of TokyoTokyoJapan

Personalised recommendations